摘要
目的观察利奈唑胺治疗耐甲氧西林金葡菌(MRSA)重症肺部炎疗效。方法选取我院ICU MRSA重症肺炎患者15例,给予利奈唑胺治疗,检测治疗前后血白细胞、乳酸、IL-1β、IL-6、TNF-α水平。结果临床有效率达73.3%,治疗前后血白细胞计数、乳酸及各炎性因子水平呈明显下降趋势,差异有统计学意义,P<0.01。结论利奈唑胺对MRSA重度肺部感染有较好的疗效。
Objective To evaluate the efficacy and safety of linezolid in the treatment of severe lung infections caused by methicillin-resistant Staphylococcus aureus （MRSA）. Methods Fifteen patients admitted to ICU due to severe lung infection caused by MRSA received linezolid treatment. WBC, lactic acid （LAC）, IL-1β, IL-6, and TNF-α levels were measured before and after treatment. Results Clinical efficacy rate was 73.3 %. The level of WBC, LAC and inflammatory cytokines decreased significantly after linezolid treatment （P〈0.01）. Conclusions Linezolid shows good efficacy in the treatment of severe lung infections caused by MRSA.
出处
《中国感染与化疗杂志》
CAS
2009年第4期264-266,共3页
Chinese Journal of Infection and Chemotherapy
关键词
利奈唑胺
耐甲氧西林金葡菌
感染
乳酸
炎性因子
linezolid
methicillin-resistant Staphylococcusaureus
inflammation
lactic acid
inflammatory cytokine
